Skip to main content

Table 7 Comparison of audiological assessments and test characteristics in ototoxicity monitoring

From: Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting

AUDIOLOGICAL ASSESSMENTS

Mid-cycle

1-month post-treatment

3-month post-treatment

6-month post-treatment

Ototoxic hearing loss (ASHA)—n (%)

80 (100)

   

NCI-CTCAE grading scale—n (%)

 No Change

77 (96.2)

50 (62.5)

30 (37.5)

13 (16.3)

 Grade 1

3 (3.8)

25 (32.3)

39 (48.8)

47 (58.8)

 Grade 2

0 (0)

4 (5.0)

5 (6.3)

9 (11.3)

 Grade 3

0 (0)

1 (1.3)

6 (7.5)

11 (13.8)

TEST CHARACTERISTICS

Sensitivitya

Specificitya

 Oto-acoustic Emissions – Right

26.09%

77.78%

 Left

22.39%

81.82%

 Word Recognition Score – Right

1.45%

100%

 Left

2.99%

90.91%

  1. a Comparisons were undertaken, using pure tone audiometry as the gold standard to detect ototoxic change at 6-month post treatment